Orally Disintegrating Tablets (ODTs) have emerged as one of the most innovative and rapidly growing dosage forms in modern pharmaceutical and nutraceutical sciences. Designed to disintegrate rapidly in the oral cavity with or without water, ODTs improve patient compliance, therapeutic effectiveness, convenience, and overall treatment experience. This comprehensive two-volume series presents a multidisciplinary overview of ODT technologies, encompassing fundamental principles, formulation strategies, advanced excipient systems, taste-masking approaches, Quality-by-Design (QbD) concepts, moisture-protective packaging, stability considerations, and commercialization aspects. The book further highlights emerging innovations, including nanotechnology-enabled ODTs, personalized medicine, precision dosing, effervescent tablets (Eff-Tabs), orally dissolving films (OTFs), orally dissolving webs (ODWs), and advanced 3D/4D printing technologies that are reshaping the future of oral drug delivery. The series also discusses the role of ODTs in improving bioavailability, enabling rapid onset of action, enhancing patient adherence, and supporting emerging polypill approaches for complex therapies and global regulatory requirements across more than fifty countries, providing valuable translational and industrial perspectives. This series stands among the first integrated and dedicated reference on ODT. Authored by internationally recognized experts, this landmark series serves as a comprehensive and up-to-date resource for researchers, formulation scientists, clinicians, industrial professionals, regulatory experts, and postgraduate students working in the field of advanced oral drug delivery systems.

Key Features
•    Comprehensive coverage of ODTs from fundamental concepts to advanced formulation in pediatric, geriatric, neurological, cardiovascular, psychiatric, and chronic disease management 
•    Highlights emerging innovations, including nanotechnology-based ODTs, Eff-Tabs, OTFs, ODWs, and 3D/4D printed dosage systems 
•    Covers QbD strategies, specialized excipients, taste masking, stability, regulatory frameworks, and clinical evaluation

Ranjita Shegokar holds a Ph.D. in Pharmaceutical Technology from SNDT University, India, and has completed PostDoctoral research at the Free University of Berlin, Germany, specializing in Pharmaceutics, Biopharmaceutics, and NutriCosmetics. She has extensive experience in R&D leadership roles at various multinational German pharmaceutical companies. Currently, she serves as the Chief Pharma Innovation Officer (CPO) at DiHeSys GmbH, Germany. She has authored numerous research articles, book chapters and has presented her work at many national and international conferences. She has filed multiple patent applications in the areas of drug delivery, drug-device combinations, drug targeting and has edited several influential books on pharmaceutical nanotechnology and drug delivery systems. Dr. Ranjita’s research excellence has been recognized with prestigious awards, including the 2025 International FIP Distinguished Pharmaceutical Science Award, the German Innovation Award (2022), and twice the German Medical Award (2025/2023).  She has also served on the jury panel for various EU grants and awards, including the Women in Pharma Awards 2025, which honor excellence in the pharmaceutical industry. Her research interests include polymeric nanoparticles, nanocrystals, lipid nanoparticles (SLNs/NLCs), nanoemulsions, cancer drug targeting, oral solid dosage forms (OSDFs), and the role of excipients in delivery systems. Dr. Ranjita’s professional focus encompasses R&D, intellectual property, trademark, innovation strategies, 2D/3D printed personalized medicines, preclinical models, and their translation into clinical trials and the market (www.ranjitas.com).

Yashwant Pathak received his Master’s and PhD in Pharmaceutical Sciences from Nagpur University, India. He completed postdoctoral training under prominent professors such as Gregory Gregoriadis at the Royal Free Hospital in London, Simon Benita at the Hebrew University of Jerusalem, and Robert Levy at the University of Michigan, USA. He serves as an Adjunct Professor at the Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia. Currently, he is a tenured professor at the Taneja College of Pharmacy, University of South Florida, Tampa, USA. Throughout his career, he has received numerous national and international awards, including the four Outstanding Faculty Award and the Global Achievement Engagement Award, excellent researcher at USF. In 2021, he was honored as a Fellow of the American Association for the Advancement of Science (FAAAS). Dr. Pathak has an extensive publication record with over 400 research articles, reviews, and book chapters. He has also edited more than 90 books in fields such as nanotechnology, drug delivery, nutraceuticals, conflict management, and cultural studies. In addition to his academic and research achievements, he is actively involved in several nonprofit organizations, including Hindu Swayamsevak Sangh, Sewa International, IACDSC, ICHRRF, and the Uberoi Foundation for Religious Studies